Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study

IntroductionThe treatment for relapsed/refractory peripheral T-cell lymphoma (r/r PTCL) is suboptimal. This open-label, multicenter, single-arm study aimed to investigate the antitumor activity and safety of camrelizumab (a PD-1 blockade) plus apatinib (an antiangiogenic agent) for patients with r/r...

Full description

Bibliographic Details
Main Authors: Yanfei Liu, Yuqin Song, Shubo Zuo, Xian Zhang, Hui Liu, Jingwen Wang, Jingbo Wang, Yongjing Tang, Wen Zheng, Zhitao Ying, Lingyan Ping, Chen Zhang, Meng Wu, Jun Zhu, Yan Xie
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Immunology
Subjects:
peripheral T-cell lymphoma
PD-1 inhibitor
apatinib
immunotherapy
camrelizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1128172/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1128172/full

Similar Items